期刊
BIOCONJUGATE CHEMISTRY
卷 20, 期 5, 页码 825-841出版社
AMER CHEMICAL SOC
DOI: 10.1021/bc800299f
关键词
-
类别
资金
- NIH
- NCI
- Center for Cancer Research
- United States Department of Health and Human Services
- NATIONAL CANCER INSTITUTE [Z01SC006353, ZIASC006353] Funding Source: NIH RePORTER
Radioimmunoimaging and therapy has been an area of interest for several decades. Steady progress has been made toward clinical translation of radiolabeled monoclonal antibodies for diagnosis and treatment of diseases. Tremendous advances have been made in imaging technologies such as positron emission tomography (PET). However, these advances have so far eluded routine translation into clinical radioimmunoimaging applications due to the mismatch between the short half-lives of routinely used positron-emitting radionuclides such as F-18 versus the pharmacokinetics of most intact monoclonal antibodies of interest. The lack of suitable positron-emitting radionuclides that match the pharmacokinetics of intact antibodies has generated interest in exploring the use of longer-lived positron emitters that are more suitable for radioimmunoimaging and dosimetry applications with intact monoclonal antibodies. In this review, we examine the opportunities and challenges of radioimmunoimaging with select longer-lived positron-emitting radionuclides such as I-124, Zr-89, and Y-86 with respect to radionuclide production, ease of radiolabeling intact antibodies, imaging characteristics, radiation dosimetry, and clinical translation potential.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据